NOVOS Labs
Targeting Aging Biology through Clinically Validated Longevity Science

The longevity sector continues to expand rapidly, yet many approaches remain focused on treating individual diseases or promoting isolated ingredients without addressing the underlying drivers of aging.
This fragmented approach often limits the ability to influence long-term health outcomes in a measurable way.

NOVOS Labs approaches this challenge by targeting aging itself as the primary driver of chronic disease. Its work is built on a systems-level understanding of aging biology, addressing multiple biological pathways simultaneously rather than focusing on single outcomes.

“At NOVOS Labs, our philosophy begins with a simple premise: aging itself is the primary driver of most chronic diseases,” says Hannah Gates, director of business development.

Moving Beyond Single-Ingredient Approaches

A key issue in the longevity supplement space is the prevalence of products built around individual compounds with limited scientific validation. Aging is a complex process involving interconnected systems, yet many solutions fail to reflect this complexity.

NOVOS Labs addresses this by focusing on the twelve biological causes of aging. Its formulations are designed to influence multiple pathways, including cellular damage, mitochondrial function, inflammation and vascular health.

This multi-pathway approach enables a broader impact on healthspan. Instead of targeting isolated markers, the company’s strategy aligns with the biological processes that influence aging across systems.

By grounding its work in established aging biology research, NOVOS Labs aims to provide interventions that reflect the complexity of human physiology.

Integrating Clinical Validation into Product Development

Another challenge for consumers is the lack of measurable outcomes in many longevity products. Supplements often rely on theoretical mechanisms or proxy biomarkers without demonstrating real physiological impact.

NOVOS Labs addresses this gap through controlled human clinical trials. Its flagship formulation, NOVOS Core, was evaluated in a randomized, double-blind, placebo-controlled study measuring validated markers of vascular aging.

Participants taking the formulation experienced statistically significant improvements in endothelial function, arterial flexibility and systolic blood pressure over six months. Endothelial function improved by approximately 2.9 percentage points compared to placebo.

These results provide measurable evidence of how a multi-pathway intervention can influence aging-related biological functions. By focusing on validated physiological markers, the company aligns its products with outcomes that are directly relevant to long-term health.

Demonstrating Impact through Multi-Pathway Formulation

The development of NOVOS Core illustrates this integrated approach. The objective was to create a formulation capable of targeting multiple biological drivers of aging, particularly those affecting cardiovascular and metabolic health.

The formulation combined bioactive compounds selected for their influence on complementary pathways. Researchers then evaluated the final product through a six-month clinical study involving healthy adults aged 40 and older.

The study demonstrated improvements across several validated markers, including flow-mediated dilation, pulse wave velocity and systolic blood pressure. The observed changes in endothelial function were comparable to ranges reported in studies of lifestyle interventions such as aerobic exercise.

This example highlights the importance of validating complete formulations rather than relying solely on ingredient-level research. It also demonstrates how clinically tested interventions can provide measurable insights into aging biology.

Looking ahead, longevity science is moving toward greater clinical validation, improved biological age measurement and integration across disciplines such as biotechnology, nutrition, and preventive health.

NOVOS Labs is positioning itself within this shift by continuing to invest in human clinical research and biomarker science. Its focus remains on translating aging biology into interventions that can be evaluated through measurable outcomes.

By combining systems-level research, multi-pathway formulations and controlled clinical studies, NOVOS Labs supports a transition toward evidence-based longevity solutions that contribute to improved healthspan and measurable physiological benefits.